ANTX — AN2 Therapeutics Inc

AN2 Therapeutics Inc (ANTX) is a biotechnology company listed on NASDAQ. It is led by Eric E. Easom, based in 1800 El Camino Real, Menlo Park, CA, United States, 94027, with about 22 employees. AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Net income was -$26.5M. ANTX currently screens at market cap $32.0M.

Use this ANTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ANTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ANTX SEC filings page. Lician reads the product cache first so this HTML stays unique to AN2 Therapeutics Inc even when a live quote feed is slow.